fingolimod has been researched along with Multiple Sclerosis, Relapsing-Remitting in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borell, H; Jin, Y; Patten, CJ; Zimmerlin, A; Zollinger, M | 1 |
| Deng, G; Elliott, JD; Guo, TB; Jia, Q; Li, C; Lin, X; Lu, H; Luan, L; Meng, Q; Ren, F; Wang, H; Xiang, JN; Xu, H; Xu, Q; Xu, X; Yang, J; Zhang, H; Zhang, W; Zhao, B; Zhao, Y | 1 |
2 other study(ies) available for fingolimod and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Fingolimod Hydrochloride; Humans; In Vitro Techniques; Mass Spectrometry; Microsomes, Liver; Molecular Structure; Multiple Sclerosis, Relapsing-Remitting; Oxidation-Reduction; Propylene Glycols; Sphingosine; Transfection | 2011 |
Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred C57BL; Multiple Sclerosis, Relapsing-Remitting; Rats; Receptors, Lysosphingolipid; Specific Pathogen-Free Organisms; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Thiadiazoles | 2012 |